Boston Scientific Corporation $BSX Position Boosted by Assetmark Inc.

Assetmark Inc. lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 10.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 198,114 shares of the medical equipment provider’s stock after purchasing an additional 19,026 shares during the period. Assetmark Inc.’s holdings in Boston Scientific were worth $21,279,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. Bessemer Group Inc. raised its stake in Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after acquiring an additional 2,899,653 shares during the period. Vanguard Group Inc. raised its stake in Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares during the period. Swedbank AB raised its stake in Boston Scientific by 114.5% during the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after acquiring an additional 1,505,019 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after acquiring an additional 1,383,524 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BSX. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Truist Financial raised their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Morgan Stanley raised their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Canaccord Genuity Group restated a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Thursday, October 23rd. Finally, UBS Group raised their price target on shares of Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $123.77.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ellen M. Zane sold 9,990 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $101.13, for a total transaction of $1,010,288.70. Following the sale, the director owned 27,035 shares of the company’s stock, valued at $2,734,049.55. The trade was a 26.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 112,891 shares of company stock valued at $11,501,887 over the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.2%

Boston Scientific stock opened at $100.81 on Friday. The firm has a 50 day simple moving average of $100.76 and a 200-day simple moving average of $102.30. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock has a market capitalization of $149.37 billion, a PE ratio of 53.91, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61. Boston Scientific Corporation has a 12-month low of $83.38 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business’s revenue was up 20.3% on a year-over-year basis. During the same period last year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.